Acute kidney injury (AKI) is common among hospitalized patients, affecting 1 in 5 adults and 1 in 4 children in the US. It is often asymptomatic and can be difficult to identify. To learn more about this public health concern, visit https://bioporto.us/aki/. Headquartered outside Boston, BioPorto Diagnostics aims to advance research with its kidney biomarker assays and antibodies available to scientific and clinical researchers in both humans and animals. All products are currently for research use only in the US; not for diagnostic procedures. Subscribe for updates: https://go.bioporto.com/subscribe/ Posts are intended for a U.S. audience. If you are from outside the United States, you are encouraged to follow BioPorto Diagnostics A/S at https://www.linkedin.com/company/bioporto-diagnostics-a-s/ Social Media Community Guidelines: https://bioporto.us/social-media/